1 INR, Prince Of Wales Hospital, Sydney, New South Wales, Australia 2 Department of Radiology, Liverpool Hospital, New South Wales, Australia 3 Department of Medicine, Prince of Wales Hospital, Sydney ...
Background Blebs significantly increase rupture risk of intracranial aneurysms. Radiomic analysis offers a robust characterization of the aneurysm wall. However, the unique radiomic profile of various ...
Correspondence to Dr Philipp Vollmuth, Department of Neuroradiology, University Hospital Heidelberg, Heidelberg 69120, Baden-Württemberg, Germany; philipp.vollmuth{at}med.uni-heidelberg.de Background ...
Correspondence to Dr Kazim H Narsinh, University of California San Francisco, San Francisco, California, USA; kazim.narsinh{at}ucsf.edu Pulsatile tinnitus is a debilitating symptom affecting millions ...
Background Cerebral arteriovenous malformation (AVM) is a cerebrovascular disorder posing a risk for intracranial hemorrhage. However, there are few reliable quantitative indices to predict hemorrhage ...
Correspondence to Dr Seán Fitzgerald, Department of Physiology, National University of Ireland Galway, Galway, Ireland; sean.fitzgerald{at}nuigalway.ie Background Balloon guide catheters (BGCs) ...
Background and purpose Flow diversion is an innovative and increasingly used endovascular treatment for intracranial aneurysms. Its initial evaluation with the first devices available showed good ...
Background Six randomized controlled trials have concluded their investigations on the efficacy and safety of endovascular thrombectomy (EVT) for patients with large infarcts. To synthesize the ...
Correspondence to Dr Alim P Mitha, Clinical Neurosciences, University of Calgary Cumming School of Medicine, Calgary, AB T2N 1N4, Canada; amitha{at}ucalgary.ca Introduction The advent of metal ...
Background Intravenous (IV) tenecteplase is increasingly being used in lieu of alteplase for acute ischemic stroke. We sought to study the influence of IV tenecteplase versus IV alteplase on the ...
Background Cangrelor, an intravenous P2Y12-receptor inhibitor, is a reversible and short-acting antithrombotic medication non-inferior to irreversible glycoprotein IIb/IIIa inhibitors (GPIs) like ...
Background Congress enacted the No Surprises Act (NSA) in 2021. The NSA relies on the ability for providers to appeal their out-of-network (OON) payment through an arbitration process known as ...